Used in clinical research for the treatment of advanced solid tumors, BMS-986176 is an investigational immuno-oncology agent designed to activate the OX40 receptor, a costimulatory target on T cells. By stimulating OX40, it enhances T cell activation, proliferation, and survival, promoting anti-tumor immune responses. It is being evaluated both as a monotherapy and in combination with other immunotherapies, such as PD-1 inhibitors, to improve outcomes in cancer patients. Its application focuses on overcoming immune suppression in the tumor microenvironment, particularly in cancers with limited response to existing immunotherapies.